Subarachnoid basal neurocysticercosis: A focus on the most severe form of the disease

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 1, 2011, Pages 123-133

  Fleury, Agnès ^a,b   Carrillo Mezo, Roger ^b   Flisser, Ana ^c   Sciutto, Edda ^a   Corona, Teresa ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Mexico; neurocysticercosis; neuroparasitology; racemose form; Taenia solium

Indexed keywords

ALBENDAZOLE; CORTICOSTEROID; DEXAMETHASONE; PRAZIQUANTEL; PREDNISONE;

BACTERIAL MENINGITIS; BEHAVIOR CHANGE; BODY FAT DISTRIBUTION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN VENTRICLE PERITONEUM SHUNT; CATARACT; CLINICAL FEATURE; CRANIAL NEUROPATHY; DIAGNOSTIC IMAGING; DISEASE SEVERITY; ELECTROLYTE DISTURBANCE; ENCEPHALITIS; GROWTH RETARDATION; HUMAN; HYDROCEPHALUS; HYPERGLYCEMIA; HYPERTENSION; INFECTION; INTRACRANIAL HYPERTENSION; MORBIDITY; MORTALITY; MYOPATHY; NEUROCYSTICERCOSIS; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PARASITE LOCALIZATION; PARKINSONISM; PATIENT ASSESSMENT; POSTOPERATIVE COMPLICATION; REVIEW; SIDE EFFECT;

ADULT; AFRICA; ANIMALS; ASIA; CENTRAL NERVOUS SYSTEM PARASITIC INFECTIONS; CHILD; CHILD, PRESCHOOL; ENDEMIC DISEASES; HUMANS; LATIN AMERICA; MAGNETIC RESONANCE IMAGING; NEUROCYSTICERCOSIS; SUBARACHNOID SPACE; TAENIA SOLIUM;

EID: 78650642081     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.150     Document Type: Review

References (110)

1. Huerta M, Avila R, Jiménez HI, et al. Parasite contamination of soil in households of a Mexican rural community endemic for neurocysticercosis. Trans. R. Soc. Trop. Med. Hyg. 102, 374-379 (2008).
2. Prasad KN, Prasad A, Verma A, Singh AK. Human cysticercosis and Indian scenario: a review. J. Biosci. 33, 571-582 (2008).
3. Praet N, Speybroeck N, Manzanedo R, et al. The disease burden of Taenia solium cysticercosis in Cameroon. PLoS Negl. Trop. Dis. 3, e406 (2009).
4. Fleury A, Moreno García J, Valdez Aguerrebere P, et al. Neurocysticercosis, a persisting health problem in Mexico. PLoS Negl. Trop. Dis. 4(8), e805 (2010).
5. Esquivel A, Diaz-Otero F, Gimenez- Roldan S. Growing frequency of neurocysticercosis in Madrid (Spain). Neurologia 20, 116-120 (2005).
6. Kraft R. Cysticercosis: an emerging parasitic disease. Am. Fam. Physician 76, 91-96 (2007).
7. Nicoletti A, Bartoloni A, Sofia V, et al. Epilepsy and neurocysticercosis in rural Bolivia: a population-based survey. Epilepsia 46, 1127-1132 (2005).
8. Fleury A, Morales J, Bobes RJ, et al. An epidemiological study of familial neurocysticercosis in an endemic Mexican community. Trans. R. Soc. Trop. Med. Hyg. 100, 551-558 (2006).
9. Fleury A, Escobar A, Fragoso G, et al. Clinical heterogeneity of human neurocysticercosis results from complex interactions among parasite, host and environmental factors. Trans. R. Soc. Trop. Med. Hyg. 104, 243-250 (2010).
10. Takayanagui OM, Odashima NS. Clinical aspects of neurocysticercosis. Parasitol. Int. 55(Suppl.), S111-S115 (2006).
11. Das K, Mondal GP, Banerjee M, Mukherjee BB, Singh OP. Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study. J. Clin. Neurosci. 14, 1172-1177 (2007).
12. Thussu A, Chattopadhyay A, Sawhney IM, Khandelwal N. Albendazole therapy for single small enhancing CSF lesions (SSECSFL) in the brain in epilepsy. J. Neurol. Neurosurg. Psychiatry 79, 272-275 (2008).
13. Nash TE, Pretell EJ, Lescano AG, et al. Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol. 7, 1099-1105 (2008).
14. Del Brutto OH, Roos KL, Coffey CS, García HH. Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann. Intern. Med. 145, 43-51 (2006).
15. Fleury A, Dessein A, Dumas M, et al. Symptomatic neurocysticercosis: host and exposure factors relating with disease heterogeneity. J. Neurol. 251, 830-837 (2004).
16. Figueroa JJ, Davis LE, Magalhaes A. Extraparenchymal neurocysticercosis in Albuquerque, New Mexico. J. Neuroimaging. DOI: 10.1111/j.1552-6569.2009. 00452.x (2009) (Epub ahead of print).
17. Shandera WX, White AC Jr, Chen JC, Diaz P, Armstrong R. Neurocysticercosis in Houston, Texas. A report of 112 cases. Medicine (Baltimore) 73, 37-52 (1994).
18. Wallin MT, Kurtzke JF. Neurocysticercosis in the United States: review of an important emerging infection. Neurology 63, 1559-1564 (2004).
19. Mendes EC, da Silva SS, Fonseca EA, de Souza HR, de Carvalho RW. Human neurocysticercosis in Baixada Fluminense, Rio de Janeiro State, Brazil. Arq. Neuropsiquiatr. 63, 1058-1062 (2005).
20. Talukdar B, Saxena A, Popli VK, Choudhury V. Neurocysticercosis in children: clinical characteristics and outcome. Ann. Trop. Paediatr. 22, 333-339 (2002).
21. Sáenz B, Ruiz-Garcia M, Jiménez E, et al. Neurocysticercosis: clinical, radiologic, and inflammatory differences between children and adults. Pediatr. Infect. Dis. J. 25, 801-803 (2006).
22. Singh G. Neurocysticercosis in South- Central America and the Indian subcontinent. A comparative evaluation. Arq. Neuropsiquiatr. 55, 349-56 (1997).
23. Bobes RJ, Fragoso G, Reyes-Montes MR, et al. Genetic diversity of Taenia solium cysticerci from naturally infected pigs of central Mexico. Vet. Parasitol. 168, 130-135 (2010).
24. Maravilla P, Gonzalez-Guzman R, Zuñiga G, et al. Genetic polymorphism in Taenia solium cysticerci recovered from experimental infections in pigs. Infect. Genet. Evol. 8, 213-216 (2008).
25. Biagi F, Briceño CE, Martinez B. Diferencias entre Cysticercus cellulosae y C. racemosus. Revista de Biología Tropical (Mexico) 9(2), 141-152 (1961).
26. Rabiela-Cervantes MT, Rivas-Hernández A, Castillo-Medina S, González-Angulo A. Morphological evidence indicating that C. cellulosae and C. racemosus are larval stages of Taenia solium. Arch. Invest. Med. (Mex) 16(1), 81-92 (1985).
27. Hinojosa-Juarez AC, Sandoval-Balanzario M, McManus DP, Monroy-Ostria A. Genetic similarity between cysticerci of Taenia solium isolated from human brain and from pigs. Infect. Genet. Evol. 8(5), 653-656 (2008).
28. Escobar A. The pathology of neurocysticercosis. In: Cysticercosis of the Nervous System. Palacios E, Rodríguez- Carbajal J, Taveras JM (Eds). Charles C Thomas Publisher, IL, USA, 27-54 (1983).
29. Hortobágyi T, Alhakim A, Biedrzycki O, Djurovic V, Rawal J, Al-Sarraj S. Cysticercosis of the fourth ventricle causing sudden death: a case report and review of the literature. Pathol. Oncol. Res. 15, 143-146 (2009).
30. DeGiorgio CM, Houston I, Oviedo S, Sorvillo F. Deaths associated with cysticercosis. Report of three cases and review of the literature. Neurosurg. Focus 12, e2 (2002).
31. Santo AH. Cysticercosis-related mortality in the State of São Paulo, Brazil, 1985- 2004: a study using multiple causes of death. Cad. Saude. Publ. 23, 2917-2927 (2007).
32. Oka Y, Fukui K, Shoda D, et al. Cerebral cysticercosis manifesting as hydrocephalus, case report. Neurol. Med. Chir. (Tokyo) 36, 654-658 (1996).
33. Estañol B, Kleriga E, Loyo M, et al. Mechanisms of hydrocephalus in cerebral cysticercosis: implications for therapy. Neurosurgery 13, 119-123 (1983).
34. Chavarria A, Fleury A, Garcia E, Marquez C, Fragoso G, Sciutto E. Relationship between the clinical heterogeneity of neurocysticercosis and the immuneinflammatory profiles. Clin. Immunol. 116, 271-278 (2005).
35. Fleury A, Escobar E, Chavarria A, Carrillo-Mezo R, Sciutto E. Cisticercosis en el ser humano. In: Cisticercosis: Guía para profesionales de la Salud. Larralde C, de Aluja A (Eds). Biblioteca de la salud, Fondo de Cultura Económica, México, 41-86 (2006).
36. Aditya GS, Mahadevan A, Santosh V, Chickabasaviah YT, Ashwathnarayanarao CB, Krishna SS. Cysticercal chronic basal arachnoiditis with infarcts, mimicking tuberculous pathology in endemic areas. Neuropathology 24, 320-325 (2004).
37. Rabiela MT, Rivas A, Castillo S, Cancino F. Anatomopathologial aspects of human brain cysticercosis. In: Cysticercosis. Present State of Knowledge and Perspectives. Flisser A, Willms K, Laclette JP, Larralde C, Ridaura C, Beltran F (Eds). Academic Press, NY, USA, 179-200 (1982).
38. McAllister JP 2nd. Neuronal damage in hydrocephalus. J. Neurosurg. 104(5 Suppl.), 297-298 (2006).
39. Joubert J. Cysticercal meningitis, a pernicious form of neurocysticercosis, which responds poorly to praziquantel. S. Afr. Med. J. 77, 528-530 (1990).
40. Oliveira JP, Morais SL, Araújo D, et al. Mood disorder due to a general medical condition with manic features. Case Report Med. 2009, 871365 (2009).
41. Agapejev S, Pouza AF, Bazan R, Faleiros AT. Clinical and evolutive aspects of hydrocephalus in neurocysticercosis. Arq. Neuropsiquiatr. 65, 674-680 (2007).
42. Forlenza OV, Filho AH, Nobrega JP, et al. Psychiatric manifestations of neurocysticercosis: a study of 38 patients from a neurology clinic in Brazil. J. Neurol. Neurosurg. Psychiatry 62, 612-616 (1997).
43. Xie S, Wei G, Zhao L. Intellectual status of patents cerebral cysticercosis. Zhonghua Yi Xue Za Zhi 76, 440-442 (1996).
44. Del Bigio MR, Wilson MJ, Enno T. Chronic hydrocephalus in rats and humans: white matter loss and behavior changes. Ann. Neurol. 53, 337-346 (2003).
45. Kondziella D, Sonnewald U, Tullberg M, Wikkelso C. Brain metabolism in adult chronic hydrocephalus. J. Neurochem. 106, 1515-1524 (2008).
46. Egawa T, Mishima K, Egashira N, et al. Impairment of spatial memory in kaolin-induced hydrocephalic rats is associated with changes in the hippocampal cholinergic and noradrenergic contents. Behav. Brain. Res. 129, 31-39 (2002).
47. Ramirez-Bermudez J, Higuera J, Sosa AL, Lopez-Meza E, Lopez-Gomez M, Corona T. Is dementia reversible in patients with neurocysticercosis? J. Neurol. Neurosurg. Psychiatry 76, 1164-1166 (2005).
48. Chang GY, Keane JR. Visual loss in cysticercosis: analysis of 23 patients. Neurology 57, 545-548 (2001).
49. Besada E, Barr R, Natu A. Bilateral disk edema with unilateral macular serous fluid secondary to neurocysticercosis. Optometry 76, 239-249 (2005).
50. Keane JR. The pretectal syndrome: 206 patients. Neurology 40, 684-690 (1990).
51. Sá DS, Teive HA, Troiano AR, Werneck LC. Parkinsonism associated with neurocysticercosis. Parkinsonism Relat. Disord. 11, 69-72 (2005).
52. Keane JR. Tremor as the result of shunt obstruction: four patients with cysticercosis and secondary parkinsonism: report of four cases. Neurosurgery 37, 520-522 (1995).
53. Curran T, Lang AE. Parkinsonian syndromes associated with hydrocephalus: case reports, a review of the literature, and pathophysiological hypotheses. Mov. Disord. 9, 508-520 (1994).
54. Racette BA, Esper GJ, Antenor J, et al. Pathophysiology of parkinsonism due to hydrocephalus. J. Neurol. Neurosurg. Psychiatry 75, 1617-1619 (2004).
55. Góngora-Rivera F, Soto-Hernández JL, Guevara P, Sotelo-Morales J. In neurocysticercosis, CSF cytokines correlate with cerebral blood flow velocities. Neurology 71, 1119-1122 (2008).
56. Alarcón F, Hidalgo F, Moncayo J, Viñán I, Dueñas G. Cerebral cysticercosis and stroke. Stroke 23, 224-228 (1992).
57. Del Brutto OH. Cysticercosis and cerebrovascular disease: a review. J. Neurol. Neurosurg. Psychiatry 55, 252-254 (1992).
58. Barinagarrementeria F, Cantú C. Frequency of cerebral arthritis in subarachnoid cysticercosis: an angiographic study. Stroke 29, 123-125 (1998).
59. Cantú C, Barinagarrementeria F. Cerebrovascular complications of neurocysticercosis. Clinical and neuroimaging spectrum. Arch. Neurol. 53, 233-239 (1996).
60. Castro-Lima H, Raicher I, Lee HW, Marchiori PE. Neurocysticercosis presenting with stroke. Arq. Neuropsiquiatr. 68, 146 (2010).
61. Barinagarrementeria F, Del Brutto OH. Neurocysticercosis and pure motor hemiparesis. Stroke 19, 1156-1158 (1988).
62. Barinagarrementeria F, del Brutto OH. Lacunar syndrome due to neurocysticercosis. Arch. Neurol. 46, 415-417 (1989).
63. Levy AS, Lillehei KO, Rubinstein D, Stears JC. Subarachnoid neurocysticercosis with occlusion of major intracranial vessels: case report. Neurosurgery 36, 183-188 (1995).
64. Monteiro L, Almeida-Pinto J, Leite I, Xavier J, Correia M. Cerebral cysticercus arteritis: five angiographic cases. Cerebrovasc. Dis. 4, 125-133 (1994).
65. Rodriguez-Carbajal J, Del Brutto OH, Penagos P, Huebe J, Escobar A. Occlusion of the middle cerebral artery due to cysticercotic angiitis. Stroke 20, 1095-1098 (1989).
66. Sawhney IM, Singh G, Lekhra OP, Mathuriya SN, Parihar PS, Prabhakar S. Uncommon presentations of neurocysticercosis. J. Neurol. Sci. 154, 94-100 (1998).
67. Garg RK, Karak B. Neurocysticercosis presenting as midbrain syndrome. J. Assoc. Physicians. India 48, 533-535 (2000).
68. Arauz A, López M, Cantú C, Barinagarrementeria F. Nonaneurysmal subarachnoid hemorrhage. Study of long-term follow-up. Neurologia 22, 502-506 (2007).
69. Kim IY, Kim TS, Lee JH, Lee MC, Lee JK, Jung S. Inflammatory aneurysm due to neurocysticercosis. J. Clin. Neurosci. 12, 585-588 (2005).
70. Soto-Hernandez JL, Gomez-Llata S, Rojas-Echeverri LA, Texeira F, Romero V. Subarachnoid hemorrhage secondary to a ruptured inflammatory aneurysm: a possible manifestation of neurocysticercosis: case report. Neurosurgery 38, 197-199 (1996).
71. Tellez-Zenteno JF, Negrete-Pulido O, Cantú C, Márquez C, Vega-Boada F, García- Ramos G. Hemorrhagic stroke associated to neurocysticercosis. Neurologia 18, 272-275 (2003).
72. Ranjith MP, Divya R, Sahni A. Isolated third cranial nerve palsy: a rare presentation of neurocysticercosis. Ir. J. Med. Sci. DOI: 10.1007/s11845-009- 0308-6 (2009) (Epub ahead of print).
73. Kim JS, Jeong SM, Moon SY, Park SH. Third cranial nerve palsy from midbrain neurocysticercosis: repeated exacerbation on tapering corticosteroids. J. Neuroophthalmol. 24, 217-220 (2004).
74. Colli BO, Martelli N, Assirati Jr JÁ, et al. Cysticercosis of the central nervous system. I. Surgical treatment of cerebral cysticercosis: a 23 years experience in the Hospital das Clínicas of Ribeirão Preto Medical School. Arq. Neuropsiquiat. 52, 166-186 (1994).
75. Chang JH, Chang JW, Park YG, Kim TS. Cysticercosis of cerebellopontine cistern: differential diagnosis using MRI. Acta Neurochir. (Wien) 146, 325-328 (2004).
76. Revuelta R, Soto-Hernández JL, Vales LO, González RH. Cerebellopontine angle cysticercus and concurrent vascular compression in a case of trigeminal neuralgia. Clin. Neurol. Neurosurg. 106, 19-22 (2003).
77. del Brutto OH. Cysticercosis of the cerebellopontine angle: treatment with single-dose praziquantel. Rev. Neurol. 3, 835-837 (2000).
78. Aguiar PH, Miura FK, Napoli PR, et al. Unusual cause for bilateral trigeminal neuralgia: unilateral racemous cysticercus of cerebellopontine angle. Case report. Arq. Neuropsiquiatr. 58, 1138-1141 (2000).
79. Lucato LT, Guedes MS, Sato JR, Bacheschi LA, Machado LR, Leite CC. The role of conventional MR imaging sequences in the evaluation of neurocysticercosis: impact on characterization of the scolex and lesion burden. Am. J. Neuroradiol. 28, 1501-1504 (2007).
80. Do Amaral LL, Ferreira RM, da Rocha AJ, Ferreira NP. Neurocysticercosis: evaluation with advanced magnetic resonance techniques and atypical forms. Top. Magn. Reson. Imaging. 16, 127-144 (2005).
81. Braga F, Rocha AJ, Gomes HR, Filho GH, Silva CJ, Fonseca RB. Noninvasive MR cisternography with fluid-attenuated inversion recovery and 100% Supplemental O2 in the evaluation of neurocysticercosis. AJNR 25, 295-297 (2004).
82. Fleury A, Hernández M, Avila M, et al. Detection of HP10 antigen in serum for diagnosis and follow-up of subarachnoidal and intraventricular human neurocisticercosis. J. Neurol. Neurosurg. Psychiatry 78, 970-974 (2007).
83. Nguekam Zoli AP, Ongolo-Zogo P, Dorny P, Brandt J, Geerts S. Follow-up of neurocysticercosis patients after treatment using an antigen detection ELISA. Parasite 10(1), 65-68 (2003).
84. Bobes RJ, Hernandez M, Marquez C, et al. Subarachnoidal and intraventricular human neurocysticercosis: application of an antigen detection assay for the diagnosis and follow-up. Trop. Med. Int. Health 11, 943-950 (2006).
85. Ostrosky-Zeichner L, Garcia-Mendoza E, Rios C, Sotelo J. Humoral and cellular immune response within the subarachnoid space of patients with neurocysticercosis. Arch. Med. Res. 27, 513-517 (1996).
86. Rodrigues V Jr, de-Mello FA, Magalhaes EP, Ribeiro SB, Marquez JO. Interleukin-5 and interleukin-10 are major cytokines in cerebrospinal fluid from patients with active neurocysticercosis. Braz. J. Med. Biol. Res. 33, 1059-1063 (2000).
87. Aguilar-Rebolledo F, Cedillo-Rivera R, Llaguno-Violante P, Torres-López J, Muñoz-Hernández O, Enciso-Moreno JA. Interleukin levels in cerebrospinal fluid from children with neurocysticercosis. Am. J. Trop. Med. Hyg. 64, 35-40 (2001).
88. Chavarría A, Fleury A, Bobes RJ, Morales J, Fragoso G, Sciutto E. A depressed peripheral cellular immune response is related to symptomatic neurocysticercosis. Microbes Infect. 8, 1082-1089 (2006).
89. Sciutto E, Chavarria A, Fragoso G, Fleury A, Larralde C. The immune response in Taenia solium cysticercosis: protection and injury. Parasite Immunol. 29, 621-636 (2007).
90. Lopez JA, Garcia E, Cortes IM, Sotelo J, Tato P, Molinari JL. Neurocysticercosis: relationship between the developmental stage of metacestode present and the titre of specific IgG in the cerebrospinal fluid. Ann. Trop. Med. Parasitol. 98, 569-579 (2004).
91. Molinari JL, Garcia-Mendoza E, de la Garza Y, Ramirez JA, Sotelo J, Tato P. Discrimination between active and inactive neurocysticercosis by metacestode excretory/secretory antigens of Taenia solium in an enzyme-linked immunosorbent assay. Am. J. Trop. Med. Hyg. 66, 777-7781 (2002).
92. Jimenez-Vazquez OH, Nagore N. Cisternal neurocysticercosis. Br. J. Neurosurg. 22, 774-775 (2008).
93. Rajshekhar V. Surgical management of neurocysticercosis. Int. J. Surg. 8, 100-104 (2010).
94. Gravori T, Steineke T, Bergsneider M. Endoscopic removal of cisternal neurocysticercal cysts. Technical note. Neurosurg. Focus 12, e7 (2002).
95. Proaño JV, Torres-Corzo J, Rodríguez-Della Vecchia R, Guizar-Sahagun G, Rangel-Castilla L. Intraventricular and subarachnoid basal cisterns neurocysticercosis: a comparative study between traditional treatment versus neuroendoscopic surgery. Childs Nerv. Syst. 25, 1467-1475 (2009).
96. Cárdenas G, Carrillo-Meza R, Jung H, Sciutto E, Soto Hernandez JL, Fleury A. Subarachnoidal Neurocysticercosis non-responsive to cysticidal drugs: a case series. BMC Neurol. 10, 16 (2010).
97. Del Brutto OH, Sotelo J. Albendazole therapy for subarachnoid and ventricular cysticercosis. Case report. J. Neurosurg. 72, 816-817 (1990).
98. Bandres JC, White AC Jr, Samo T, Murphy EC, Harris RL. Extraparenchymal neurocysticercosis: report of five cases and review of management. Clin. Infect. Dis. 15, 799-811 (1992).
99. Del Brutto OH. Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients. J. Neurol. Neurosurg. Psychiatry 62, 659-661 (1997).
100. Proano JV, Madrazo I, Avelar F, Lopez-Felix B, Diaz G, Grijalva I. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N. Engl. J. Med. 345, 879-885 (2001).
101. Gongora-Rivera F, Soto-Hernandez JL, Gonzalez Esquivel D, et al. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology 66, 436-438 (2006).
102. Marquez-Caraveo C, Gongora-Rivera F, Santos Zambrano J, Hernandez R, Soto-Hernandez JL. Pre-treatment with corticosteroids and a single cycle of high dose albendazole for subarachnoidal cysticercosis. J. Neurol. Neurosurg. Psychiatry. 75, 938-939 (2004).
103. Jung H, Cárdenas G, Sciutto E, Fleury A. Medical treatment for neurocysticercosis: drugs, indications and perspectives. Curr. Top. Med. Chem. 8, 424-433 (2008).
104. Suastegui-Roman RA, Soto-Hernandez JL, Sotelo J. Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study. J. Neurosurg. 84, 629-633 (1996).
105. Mitre E, Talaat KR, Sperling MR, Nash TE. Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis. Clin. Infect. Dis. 44, 549-553 (2007).
106. Sotelo J, Flisser A. Neurocysticercosis Practical Treatment Guidelines. CNS Drug 7, 17-25 (1997).
107. Sotelo J, Marin C. Hydrocephalus secondary to cysticercotic arachnoiditis. J. Neurosurg. 66, 686-689 (1987).
108. Kelley R, Duong DH, Locke GE. Characteristics of ventricular shunt malfunctions among patients with neurocysticercosis. Neurosurgery 50, 757-761 (2002).
109. Keane JR. Tremor as the result of shunt obstruction: four patients with cysticercosis and secondary parkinsonism: report of four cases. Neurosurgery 37, 520-522 (1995).
110. Stanbury RM, Graham EM. Systemic corticosteroid therapy - side effects and their management. Br. J. Ophthalmol. 82, 704-708 (1998).